

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

Anixa Biosciences, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

03528H109

(CUSIP Number)

Michael Catelani
c/o Anixa Biosciences, Inc., 3150 Almaden Expressway, Suite 250
San Jose, CA, 95118
408-708-9808

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

01/05/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 03528H109

1	Name of reporting person Michael Catelani
2	Check the appropriate box if a member of a Group (See Instructions) <input type="checkbox"/> (a) <input type="checkbox"/> (b)
3	SEC use only

4	Source of funds (See Instructions) PF	
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) <input type="checkbox"/>	
6	Citizenship or place of organization UNITED STATES	
Number of Shares Beneficially Owned by Each Reporting Person With:	7	Sole Voting Power 2,468,103.00
	8	Shared Voting Power 0.00
	9	Sole Dispositive Power 2,468,103.00
	10	Shared Dispositive Power 0.00
11	Aggregate amount beneficially owned by each reporting person 2,468,103.00	
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions) <input type="checkbox"/>	
13	Percent of class represented by amount in Row (11) 7.0 %	
14	Type of Reporting Person (See Instructions) IN	

SCHEDULE 13D

Item 1. Security and Issuer

(a) Title of Class of Securities:

Common Stock

(b) Name of Issuer:

Anixa Biosciences, Inc.

(c) Address of Issuer's Principal Executive Offices:

3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE, CALIFORNIA , 95118.

Item 5. Interest in Securities of the Issuer

(a) 7.0%

(b) 2,468,103 shares, consisting of: (i) 44,500 shares of common stock held directly and (ii) 2,423,603 shares of common stock issuable upon exercise of stock options held directly by Reporting Person and exercisable within 60 days.

(c) As of the date hereof, Mr. Catelani beneficially owns 2,468,103 shares of the Issuer, consisting of 44,500 shares of common stock held directly and 2,423,603 shares of common stock issuable upon exercise of stock options held directly and exercisable within 60 days. Such shares represent a total of 7.0% of the Issuer's outstanding shares of common stock, an increase from the 5.25% reported on Mr. Catelani's Schedule 13D. The change in ownership is the result of market purchases, the vesting of previously outstanding stock options and a change in the number of stock options that are not yet exercisable but will be exercisable within 60 days. The triggering event for this filing was the granting on January 5, 2026 of a stock option to Mr. Catelani to purchase up to 175,000 shares of common stock at a price of \$3.18 per share.

Mr. Catelani has the sole power to vote or direct the vote of, and to dispose or direct the disposition of, the entirety of the number of shares indicated immediately above. There are no other persons known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Michael Catelani

Signature: /s/ Michael Catelani
Name/Title: Michael Catelani
Date: 01/06/2026